The generic drug segment, a key driver of Amneal’s business, has shown particularly impressive growth. Analysts project a 17% growth for the generic segment in the third quarter of 2024 ...

The Generic (Gx) segment, in particular, has been a standout performer for Amneal. Analysts project that this segment experienced about 17% growth in the third quarter of 2024, with the Injectable ...

Amneal Pharmaceuticals (AMRX) is experiencing significant financial growth by focusing on making generic drugs more affordable and accessible—a ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.74 billion, has been making significant strides in the pharmaceutical ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates ...

Also Read: Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock It clocked a net loss of $31 million compared to a net loss of $99 million ...

Amneal is introducing mesalamine 800 mg delayed-release tablets, which is a generic of Asacol HD. The medication is an aminosalicylate indicated for the treatment of moderately active ulcerative ...

Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars On Friday, Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported fourth ...

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The generic pharmaceutical industry operates on ...

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December ...